Herantis Pharma: Announces positive phase Ia data - Redeye
Redeye is positive towards the top-line data from the phase Ia trial with HER-096 presented by Herantis. We raise our base case and look forward to an exciting 2024.
ANNONS
Redeye is positive towards the top-line data from the phase Ia trial with HER-096 presented by Herantis. We raise our base case and look forward to an exciting 2024.